Shukra Medtech Reports Robust Q2 FY27 Results Driven by Exports Expansion
Shukra Pharmaceuticals Ltd · Press Release · 05 Nov 2026, 8:05 pm
Shukra Medtech Reports Robust Q2 FY27 Results Driven by Exports Expansion Shukra Medtech reported a 652% YoY surge in standalone Q2 FY27 revenue to ₹44.20 crore, compared to ₹5.88 crore in Q2 FY26. EBITDA turned positive to ₹22.01 crore with a 49.8% margin, while PAT jumped 573% YoY to ₹16.01 crore. For H1 FY27, revenue expanded 501% YoY to ₹67.73 crore and PAT surged 811% YoY to ₹31.04 crore. Top-line growth was primarily driven by export expansion, alongside segment contributions of ₹32.27 crore from pharmaceuticals and ₹12.51 crore from MedTech.
Original exchange filing (PDF)
More announcements from Shukra Pharmaceuticals Ltd
- Approval for Change of Name of Company on National Stock Exchange Limited dated 16th November 2026 · 17 Nov 2026
- Shukra Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 05 Nov 2026
- Reg 32 · 05 Nov 2026
- Unaudited financial results for the quarter ended 30th September 2026 · 05 Nov 2026
- Unaudited financial results for the quarter ended 30th September 2026 · 05 Nov 2026
- SHUKRA PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 . · 04 Nov 2026
- The Board Meeting to be held on 03/11/2026 has been revised to 04/11/2026 The Board Meeting to be held on 03/11/2026 has been revised to 04/11/2026 · 04 Nov 2026
- SHUKRA PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 . · 04 Nov 2026
